|
|
Volumn 17, Issue 3, 2008, Pages 269-283
|
|
Discontinued drugs in 2006: Oncology drugs
|
|
Author keywords
Atamestane; AZD 5438; AZD3409; BW 114; Canertinib dihydrochloride; Del 1; DJ 927; G 024856; INNO 105; MG 98; MLN 2704; NS 3728; PANVAC VF; PX 104.1; SK 962; WP 760
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
AROMATASE INHIBITOR;
ATAMESTANE;
AZD 3409;
AZD 5438;
BW 114;
CANERTINIB;
CHLORIDE CHANNEL BLOCKING AGENT;
CL 1033;
CYCLIN DEPENDENT KINASE INHIBITOR;
DEL 1 MONOCLONAL ANTIBODY;
DJ 927;
DNA METHYLTRANSFERASE INHIBITOR;
FALIMAREV PLUS INALIMAREV;
G 024856;
GROWTH FACTOR;
IMMUNOSTIMULATING AGENT;
INNO 105;
INTERCALATING AGENT;
MG 98;
MLN 2704;
NS 3728;
PROSTATE SPECIFIC MEMBRANE ANTIGEN;
PROTEIN FARNESYLTRANSFERASE INHIBITOR;
PROTEIN INHIBITOR;
PX 1041;
SONIC HEDGEHOG PROTEIN;
TAXANE DERIVATIVE;
UNCLASSIFIED DRUG;
WP 760;
NEW DRUG;
ANGIOGENESIS;
ANTIANGIOGENIC ACTIVITY;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BASAL CELL CARCINOMA;
BRAIN CANCER;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CLINICAL TRIAL;
COLORECTAL CANCER;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG STRUCTURE;
DRUG TARGETING;
DRUG WITHDRAWAL;
HEAD AND NECK CANCER;
HUMAN;
LUNG NON SMALL CELL CANCER;
MELANOMA;
MESOTHELIOMA;
NONHUMAN;
PANCREAS CANCER;
SARCOMA;
SKIN TOXICITY;
SOLID TUMOR;
STOMACH CANCER;
THYROID CANCER;
UNSPECIFIED SIDE EFFECT;
CHEMISTRY;
DRUG DESIGN;
TREATMENT FAILURE;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
DRUG DESIGN;
DRUGS, INVESTIGATIONAL;
HUMANS;
TREATMENT FAILURE;
|
|
EID: 40949135630
PISSN: 13543784
EISSN: None
Source Type: Journal
DOI: 10.1517/13543784.17.3.269 Document Type: Article |
|
Times cited : (5)
|
|
References (10)
|
